



HHS Public Access

Author manuscript

J Antibiot (Tokyo). Author manuscript; available in PMC 2014 August 01.

Published in final edited form as:

J Antibiot (Tokyo). 2014 February ; 67(2): 147–151. doi:10.1038/ja.2013.111.

A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity

Zakuan Z. Deris^{a,b}, Jesmin Akter^a, Sivashangarie Sivanesan^a, Kade D. Roberts^c, Philip E. Thompson^c, Roger L. Nation^{a,#}, Jian Li^{a,#}, and Tony Velkov^{a,#,*}

^aDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

^bDepartment of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia

^cMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences

Abstract

Polymyxin B and colistin were examined for their ability to inhibit the type II NADH-quinone oxidoreductases (NDH-2) of three species of Gram-negative bacteria. Polymyxin B and colistin inhibited the NDH-2 activity in preparations from all of the isolates in a concentration-dependent manner. The mechanism of NDH-2 inhibition by polymyxin B was investigated in detail with *E. coli* inner membrane preparations and conformed to a mixed inhibition model with respect to ubiquinone-1 and a non-competitive inhibition model with respect to NADH. These suggest inhibition of vital respiratory enzymes in the bacterial inner membrane represents one of the secondary modes of action for polymyxins.

Keywords

type II NADH-quinone oxidoreductase; polymyxin B; colistin; *Escherichia coli*; *Klebsiella pneumoniae*; *Acinetobacter baumannii*

Introduction

The absence of novel antibiotics in the drug discovery pipeline and the increasing incidence of infection caused by multi-drug resistant (MDR) Gram-negative bacteria has lead us to re-evaluate 'old' antibiotics, such as polymyxin B and colistin, which retain activity against these MDR pathogens^{1–3}.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

* **Corresponding Author.** Mailing address: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia. Phone: +61 3 9903 9539. Fax: +61 3 9903 9583. Tony.Velkov@monash.edu.

Joint senior authors

Although cationic peptides such as the polymyxins are traditionally thought of as outer membrane-active agents⁴, the bacterial outer membrane is not necessarily the sole target for their mode of action⁵⁻⁷. Secondary targets involved in the bactericidal activity of polymyxins remain poorly characterized⁸. Based on available evidence, one possible secondary mode of action of polymyxin B and colistin in Gram negative bacteria involves the inhibition of bacterial respiration^{9, 10}.

In general, the bacterial respiratory chain consists of three complexes with quinones and reduced nicotinamide adenine dinucleotide (NADH) acting as the carriers that shuttle electrons and protons between large protein complexes¹¹⁻¹⁵. The exact organization of enzymes varies among different bacteria¹¹⁻¹³. In complex 1, three inner membrane respiratory enzymes of the NADH oxidase family have been identified: proton-translocating NADH-quinone (Q) oxidoreductase (NDH-1), NADH-Q oxidoreductase which lacks an energy-coupling site (NDH-2) and the sodium-translocating NADH-Q oxidoreductase^{11-13, 15}.

The inhibition of NADH oxidase enzymes family by polymyxin B was reported for Gram-positive *Bacillus spp.* and *Mycobacterium spp.*¹⁶⁻¹⁹. Moreover, a recent study in *Acinetobacter baumannii* found the mechanism of bacterial killing by polymyxins is mediated by release of hydroxyl radicals that might be related to aberrant bacterial respiration²⁰. Taken together, these findings open up the possibility that a secondary mode of action of polymyxin B and colistin against Gram-negative bacteria may involve inhibition of vital respiratory enzymes in the bacterial inner membrane.

The aim of this study was to investigate the ability of polymyxin B, colistin, colistin methanesulfonate (CMS) and the nona-peptides of polymyxin B and colistin (Figure 1) to inhibit NDH-2 oxidoreductase activity in the inner membrane of the Gram-negative bacteria *E. coli*, *Klebsiella pneumoniae* and *Acinetobacter baumannii*. To the best of our knowledge, the present study is the first to investigate the activity of this series of polymyxin analogues against the NDH-2 respiratory enzyme of Gram-negative bacteria.

Materials and Methods

Polymyxins

Polymyxin B sulphate (lot # 1312290; 6500 U/mg), colistin sulphate (lot # 070M1499V; 23,690 U/mg) and polymyxin B nona-peptide (lot # 088K4054) were purchased from Sigma-Aldrich ((St. Louis, MO), whereas CMS (batch # 143412, ~12500 U/mg) was purchased from Link Pharma, Auckland, New Zealand. Polymyxin B₁, B₂ and colistin nona-peptide was prepared and purified by HPLC as previously described^{21, 22}. All polymyxins were diluted in deionised water and all except CMS were kept in 4°C up to a month as they are stable in this condition.²³ CMS was prepared immediately before experiment as CMS is a pro-drug²⁴.

Bacterial isolates

K. pneumoniae ATCC 13883 (KpS) and *A. baumannii* ATCC 19606 (AbS) was obtained from the American Type Culture Collection (Rockville, MD, USA), while *E. coli* DH5α

(Ec) strain was employed in this study. Colistin-resistant variant of *K. pneumoniae* ATCC 13883 (designated 13883R; KpR) was selected by direct plating of parent strain onto Mueller Hinton agar containing 10 mg/L colistin (Media Preparation Unit, The University of Melbourne, Parkville, Australia)²⁵ and further increased resistance was produced by serial subculture in cation-adjusted Mueller Hinton broth (CAMHB; containing 23.0 mg/L Ca²⁺ and 11.5 mg/L Mg²⁺ [Oxoid, Hampshire, England]) with increase concentration of colistin up to 100 mg/L (~70 µM)²⁶. The stability of resistant variant was tested by four times subculture of stationary phase in colistin-free media. Isolates were stored in tryptone soy broth (Oxoid) with 20% glycerol (Ajax Finechem, Seven Hills, NSW, Australia) at -80°C. Minimum inhibitory concentrations (MICs) for polymyxin B and colistin against the test strains were determined for each isolate in two replicates in CAMHB via broth microdilution and the MIC of working isolates are documented in Supplementary Table 1²⁷.

Inner membrane preparation

Bacterial strains from frozen stock cultures were inoculated onto nutrient agar plates (Media Preparation Unit) and incubated for 18 h aerobically at 37°C. The colonies were successively sub-cultured into Mueller Hinton broth (Oxoid) and incubated aerobically for 17–24 h at 37°C to obtain approximately 1–3 g wet weight of cells. Cells were harvested from the growth medium by centrifugation in sterile centrifuge bottles at 3220 ×g for 30 min at 4°C (Eppendorf 5810R, Eppendorf AG, Hamburg, Germany). Cells were washed at least three times in gradual reduce of volume 100 mL, 50 mL and 20 mL of sterile saline. To prepare spheroplasts, the cells were resuspended at a ratio of 1 g wet weight per 10 mL of 30 mM Tris-HCl (Trizma base, Sigma-Aldrich), pH 8.0, containing 20% sucrose at 21°C²⁸. EDTA iron (III) salt (Sigma-Aldrich), pH 7.5, and lysozyme (Sigma-Aldrich) were added to achieve final concentrations of 10 mM and 1 mg/mL, respectively, and the suspensions were retained for 30 min at 21°C. The spheroplast suspensions were centrifuged at 16000 ×g for 30 min at 4°C (Beckmann Avanti J-25, Rotor RA25.50, Beckman Coulter, Brea, CA, USA). The spheroplast pellet was resuspended in 20 mL of 0.1 M phosphate buffer pH 7.5, containing 20% sucrose. DNase (Sigma-Aldrich) and magnesium sulphate (AnalaR, Merck Pty. Limited, Kilsyth, Australia) were added to achieve a final concentration of 3 mg/mL and 20 mM, respectively; and the spheroplast mixture were incubated at 37°C for 30 min. The spheroplasts were disrupted by ultrasonication for 10 min, pulsation at 9 sec/9 sec on-off, on ice using a VCX 500 sonicator 19 mm probe (Sonics Vibracell, Sonics & Materials, Inc., Newtown, CT, USA). The lysate was centrifuged at 75000 ×g for 30 min at 4°C (Beckmann Avanti) to obtain crude inner membrane. Membranes were resuspended at 10 mg wet weight per mL into 50 mM phosphate buffer (pH 7.5) which contained 5 mM magnesium sulphate. The cell debris was removed by centrifugation at 800 ×g for 10 min. Inner membranes were isolated by centrifugation at 75000 ×g for 1 h at 4°C and the membrane preparation was stored at -80°C until required for experiments. Protein was quantified via Bradford assay (Biorad Protein Assay, Hercules, CA).

NADH-quinone oxidoreductase activity assay

Enzymatic activity measurements were performed at 37°C in 96-well plates (Greiner Bio-one, Frickenhausen, Germany). Membrane-bound NADH-quinone oxidoreductase activity was measured as previously reported^{11, 29}. Briefly, bacterial membranes (3 mg/mL) were

resuspended in the above phosphate buffer containing magnesium sulphate and dispensed into the wells in presence of 200 μM ubiquinone-1 (Q_1) and 5 mM potassium cyanide (KCN). A polymyxin or analogues was added as desired and the reaction mixture was incubated for 5 min at 24°C. The reaction was initiated by adding 200 μM NADH that was prepared immediately before each experiment. The NADH oxidase activity was measured by following the decrease in absorbance at 340 nm ($\text{NADH } \epsilon=6.22 \text{ mM}^{-1}\text{cm}^{-1}$) using a VersaMax Microplate Reader with SoftMax[®] Pro Microplate Data Acquisition Software (Molecular Devices, Sunnyvale, CA, USA). For inhibition studies with polymyxins, the NADH or Q_1 concentrations were varied from 0–250 μM .

Data analysis

All kinetic data of enzyme were analysed using Graphpad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). For the NADH oxidase inhibition activity, we plotted the percentage of NDH-2 activity vs. the concentration of polymyxin in logarithm form and the concentration of polymyxin that cause 50% reduction of enzyme activity (IC_{50}) was estimated by concentration-response equation below:³⁰

$$Y=100/[1+10^{((\text{LogIC}_{50}-X)*h)}] \quad (\text{Eq 1})$$

Where, Y is the percentage of NDH-2 activity inhibition, X is logarithm of polymyxin concentration and h is Hill coefficient.

The following model for reversible inhibition was applied to the kinetic data:³⁰

$$v=[V_{max} * S / (1 + [I] / (\alpha K_i))] / ([K_m * (1 + [I] / K_i) / (1 + [I] / (\alpha K_i))] + S) \quad (\text{Eq 2})$$

Where, v is the enzyme velocity, V_{max} is the maximum enzyme velocity without inhibitor; K_m is the Michaelis-Menten constant; K_i is the inhibition constant; $[I]$ is the concentration of inhibitor; $[S]$ is the concentration of substrate and α is mechanism determinant, which is diagnostic of the mode of inhibition. The non-competitive mode of inhibition is indicated when $\alpha=1$ (inhibitor displays equal affinity for both free enzyme and enzyme substrate complex); and mixed inhibition when $\alpha \neq 1$ in which if $\alpha > 1$ the inhibitor preferentially binds to the free enzyme and if $\alpha < 1$ the inhibitor has a greater affinity to enzyme-substrate complex³⁰.

Results

Inhibition of NDH-2 activity by polymyxins

To test if polymyxins can inhibit NDH-2 activity in the inner membranes of three different Gram-negative bacterial species, the electron transport chain was blocked with KCN and NADH oxidation in the presence of 200 μM Q_1 was monitored spectrophotometrically. Polymyxin B, B1, B2 and colistin inhibited NDH-2 activity in a concentration-dependent manner (Figure 2); the calculated IC_{50} values are documented in Table 1. The IC_{50} values for the inner membrane preparations from the paired polymyxin-susceptible and -resistant *K. pneumoniae* strains were comparable for each of polymyxin B and colistin (Table 1; Figure 2). We also examined the effect of polymyxin B and colistin nonapeptides and CMS on

NDH-2 activity. The NDH-2 activity was not inhibited by CMS, polymyxin B nona-peptide and colistin nona-peptide (Table 1). Control data with specific inhibitors and selective cofactors for each of the complex 1 NDH enzymes, demonstrated that our assay system is monitoring NDH-2 activity and that the polymyxin inhibition we report is specific for NDH-2 and not NDH-1 or the sodium-dependant quinone oxidoreductase activity (Supplementary Figure 1).³¹ Rotenone (20 μM) a specific inhibitor of the NDH-1 and the sodium-dependant quinone oxidoreductase (note that NDH-2 is insensitive to rotenone)^{12–14, 32–34}, did not inhibit the NADH dehydrogenase activity of the membranes (Supplementary Figure 1). As secondary controls, we showed that the NDH-2 selective inhibitor, diphenyliodonium iodide (DPI) (25 μM),^{35, 36} inhibited the Q_1 dependent NADH dehydrogenase activity of the membranes (Supplementary Figure 1). Synergy between the polymyxins and DPI was not evident in a disc diffusion assay (Supplementary Figure 2). This is most likely due to the fact that polymyxins operate via a very different primary mechanism at the level of the outer membrane compared to DPI, whose primary mode of action involves NDH-2 inhibition.^{35, 36} Moreover, deamino-NADH, a NADH cofactor analog that can only be utilized by NDH-1 and the sodium-dependant quinone oxidoreductase; and sodium (20 mM) did not impact the NDH-2 activity of the membranes (Supplementary Figure 1)^{31, 33, 34}.

To define the mode of inhibition by polymyxin B, we performed steady-state inhibition kinetic analysis for both NADH and Q_1 using *E. coli* inner membrane preparations. The Q_1 dependent NDH-2 activity displayed Michaelis-Menten kinetics with an apparent K_m of 11.0 μM and V_{max} 63.4 units/mg protein for Q_1 (Supplementary Figure 3A). The V_{max} were reduced to 39.1 and 25.6 units/mg protein and K_m increased to 14.1 μM and 16.3 μM in the presence of polymyxin B 50 μM and 250 μM , respectively. The double reciprocal plot of polymyxin B inhibition kinetics in terms of Q_1 shows the lines converge to the left of the y axis, above the x axis, which is diagnostic of a mixed mode of inhibition in terms of Q_1 (Figure 3A). Moreover, the α value from the fit of Eq. 2 was 2.32 ± 1.28 , which is diagnostic of a mixed mode of inhibition for Q_1 . The NADH dependent NDH-2 activity displayed Michaelis-Menten kinetics with an apparent K_m of 228 μM and V_{max} 64.3 units/mg protein for NADH. With fixed 200 μM Q_1 , the V_{max} values were 43.7 and 15.4 units/mg; and the K_m were 195 and 185 μM NADH in the presence of polymyxin B 50 and 250 μM , respectively (Supplementary Figure 3B). Our K_m and V_{max} values for *E. coli* NDH-2 are in agreement with values previously reported for *E. coli* NDH-2 from native membranes and purified *E. coli* NDH-2 enzyme^{29, 37}. The double reciprocal plot of polymyxin B inhibition kinetics in terms of NADH showed the slopes of the lines converged to the left of the y axis and on the x axis, which is consistent with a non-competitive mode of inhibition (Figure 3B). The α value from the fit of Eq. 2 was 0.70 ± 0.38 , which is diagnostic of a non-competitive mode of inhibition for NADH.

Discussion

It is well established that the initial site of action for the polymyxins is the outer membrane⁸. Nevertheless, the antibacterial action of polymyxins on Gram-negative bacteria is believed to involve multiple sites of action⁸. Our data suggest that one of the secondary target sites of polymyxins is the type II NADH-quinone oxidoreductase respiratory enzyme that forms an

integral part of the bacterial electron transport pathway. - Type II NADH-quinone oxidoreductases are flavoenzymes that are found in the respiratory chain of a variety of organisms²⁹. NDH-2 is often referred to as the 'alternative' NADH quinone reductase, that does not pump protons across the inner membrane²⁹. It is acknowledged that the similar NDH-2 enzyme is an important target for antimicrobial development, particularly against malaria and tuberculosis³⁸⁻⁴³, but the study of this enzyme in Gram negative bacilli is very limited.

The IC₅₀ values for the inhibition by polymyxin B and colistin of NDH-2 activity in inner membrane of three different Gram-negative bacterial species were in most part comparable, indicating that inter-species differences in NDH-2 do not impact the inhibitory activity of the polymyxins. Polymyxin B was a better inhibitor compared to colistin, which is in line with reported results with the Gram-positive *M. smegmatis* NDH-2¹⁸. Notably also colistin inhibited NADH-quinone oxidoreductase activity in the polymyxin-susceptible strain of *K. pneumoniae* with a comparable IC₅₀ to that of the polymyxin-resistant strain, suggesting polymyxin resistance in these strains is not at the level of the inner membrane respiratory enzymes. Our previous study had indicated that the resistant derivative of *K. pneumoniae* exhibited less negative charge than the wild type that lead to failure of polymyxin interaction at the outer membrane²⁵.

The loss of inhibitory activity seen with the polymyxin nonapeptide and CMS suggests that the *N*-terminal fatty acyl chain and the positive charges of the polymyxin molecule are critical for NDH-2 inhibitory activity⁸. Although polymyxin B and colistin display high IC₅₀ values for NDH-2 inhibition, under *in vivo* conditions there remains the possibility that very high local concentrations of the antibiotic can accumulate at the site of infection that fall within these IC₅₀ value ranges. Coincidentally, we have garnered *in vitro* evidence that suggests that polymyxins can accumulate in the inner membrane of Gram-negative bacteria (manuscript submitted for publication). Therefore, the high IC₅₀ values do not dismiss the possibility that NDH-2 represents one of the secondary pathways that is targeted once the polymyxin penetrates the outer membrane.

NDH-2 contains a non-covalently bound flavin adenine dinucleotide prosthetic group (FAD) and catalyses the oxidation of NADH to NAD⁺ coupled to the reduction of quinone⁴⁴⁻⁴⁷. Available steady-state kinetic evidence indicates the reaction kinetics of NDH-2 follows a 'ping-pong' (double displacement) reaction mechanism where the enzyme interacts with NADH and quinone separately, and does not form a ternary complex with both substrates⁴⁴⁻⁴⁷. This mechanism predicts that NDH-2 firstly catalyses the reduction of the prosthetic group FAD with NADH to FADH₂, releasing NAD⁺; NDH-2 then binds Q₁ which accepts electrons from FADH₂⁴⁴⁻⁴⁷. The non-competitive inhibition with respect to NADH indicates polymyxins bind to a site on the enzyme away from the NADH binding site which slows the reaction rate. In line with a non-competitive mode of inhibition, our results showed polymyxin inhibition decreases the V_{max} , but does not markedly change the K_m ³⁰. Furthermore, a non-competitive inhibition mode of action indicates that the polymyxin likely binds with equal affinity to either the free enzyme or the enzyme-substrate complex. Similarly, the mixed inhibition mode observed with respect to Q₁ involves binding to an allosteric site on either the free enzyme or enzyme-substrate complex. However, as the

binding preference for the free enzyme or enzyme-substrate complex is disproportional, this inhibition mode usually affects both the K_m and V_{max} , as per our results³⁰. Polymyxin B inhibition increased the K_m for Q_1 , together with the α value >1 , which indicates polymyxin B favours binding to the free enzyme which lowers the apparent affinity of NDH-2 for Q_1 and thereby decreases the apparent maximum enzyme reaction rate (V_{max}).

The structure of the polymyxins (cyclic peptides) being distinct from those of the NDH-2 substrates NADH and Q_1 is supportive of the inhibition kinetic data, in that they are unlikely to compete for the same sites on the enzyme. Our kinetic data are in line with the reported data for *Gluconobacter oxydans* which showed inhibition by gramicidin S and scopafungin were non-competitive with respect to NADH¹⁷. Scopafungin, which like polymyxin B and colistin possesses a cyclic ring and a long acyl chain in its structure, displayed a mixed inhibition mode with respect to ubiquinone, whereas gramicidin S was a competitive inhibitor¹⁷.

We have shown for the first time that the secondary mechanism of polymyxins involves inhibition of NDH-2 activity in inner membrane of Gram negative bacteria. Further studies are underway to elucidate the effect of polymyxins on NADH oxidoreductases downstream of NDH-2 and polymyxin response networks which will shed further light on the role of inner membrane respiratory enzymes in polymyxin mediated bacterial cell death. In view of the dry antibiotic pipe-line, together with the increasing incidence of multidrug resistant in Gram-negative bacteria, NDH-2 represents an important target that can be exploited for the development of new antibiotics against these problematic pathogens.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

T.V, R.L.N, and J.L, are supported by the Australian National Health and Medical Research Council (NHMRC). J.L. is an Australian NHMRC Senior Research Fellow. T.V. is an Australian NHMRC Industry Career Development Research Fellow. Z.Z.D is a PhD candidate co-sponsored by the Malaysian Government and Universiti Sains Malaysia.

Abbreviations

CMS	colistin methanesulfonate
NADH	nicotinamide adenine dinucleotide reduced
NDH-2	type II NADH-quinone oxidoreductases
Q_1	ubiquinone-1


References

1. Li J, Nation RL. Old Polymyxins Are Back: Is Resistance Close? *Clinical Infectious Diseases*. 2006; 43(5):663–664. [PubMed: 16886164]
2. Li J, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *The Lancet Infectious Diseases*. 2006; 6(9):589–601. [PubMed: 16931410]

3. Lim LM, et al. Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. *Pharmacotherapy*. 2010; 30(12):1279–1291. [PubMed: 21114395]
4. Hancock REW, et al. Peptide antibiotics. *The Lancet*. 1997; 349(9049):418–422.
5. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defenses. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(16):8856–8861. [PubMed: 10922046]
6. Cho, J.; Kim, S. *Advances in Molecular and Cellular Microbiology* No. 18. Wallingford: CABI; 2010. Non-membrane targets of antimicrobial peptides: novel therapeutic opportunities?; p. 128-140.
7. Otvos L. Antibacterial peptides and proteins with multiple cellular targets. *Journal of Peptide Science*. 2005; 11(11):697–706. [PubMed: 16059966]
8. Velkov T, Thompson PE, Nation RL, Li J. Structure–Activity Relationships of Polymyxin Antibiotics. *Journal of Medicinal Chemistry*. 2010; 53(5):1898–1916. [PubMed: 19874036]
9. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and Related Peptide Antibiotics. *Annual Review of Biochemistry*. 1977; 46(1):723–763.
10. Teuber M. Action of polymyxin B on bacterial membranes. *Archives of Microbiology*. 1974; 100(1):131–144.
11. Kim MS, Kim YJ. Enzymatic Properties of the Membrane bound NADH Oxidase System in the Aerobic Respiratory Chain of *Bacillus cereus*. *Journal of Biochemistry and Molecular Biology*. 2004; 37(6):753–756. [PubMed: 15607037]
12. Kerscher, S.; Dröse, S.; Zickermann, V.; Brandt, U. The Three Families of Respiratory NADH Dehydrogenases *Bioenergetics*. In: Schäfer, G.; Penefsky, H., editors. *Results and Problems in Cell Differentiation*. Springer Berlin: Heidelberg; 2008. p. 185-222.
13. Yagi T, Yano T, Di Bernardo S, Matsuno-Yagi A. Prokaryotic complex I (NDH-1), an overview. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*. 1998; 1364(2):125–133. [PubMed: 9593856]
14. Yagi T. Bacterial NADH-quinone oxidoreductases. *Journal of Bioenergetics and Biomembranes*. 1991; 23(2):211–225. [PubMed: 2050655]
15. Yagi T, Matsuno-Yagi A. The proton-translocating NADH-quinone oxidoreductase in the respiratory chain: the secret unlocked. *Biochemistry*. 2003; 42(8):2266–2274. [PubMed: 12600193]
16. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. *Cellular and Molecular Life Sciences*. 2009; 66(23):3821–3826. [PubMed: 19701717]
17. Mogi T, et al. Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II). *FEMS Microbiology Letters*. 2009; 291(2):157–161. [PubMed: 19076229]
18. Mogi T, et al. Polymyxin B Identified as an Inhibitor of Alternative NADH Dehydrogenase and Malate: Quinone Oxidoreductase from the Gram-positive Bacterium *Mycobacterium smegmatis*. *Journal of Biochemistry*. 2009; 146(4):491–499. [PubMed: 19564154]
19. Tochikubo K, Yasuda Y, Kozuka S. Decreased Particulate NADH Oxidase Activity in *Bacillus subtilis* Spores After Polymyxin B Treatment. *Journal of General Microbiology*. 1986; 132(2): 277–287. [PubMed: 3011961]
20. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid Killing of *Acinetobacter baumannii* by Polymyxins Is Mediated by a Hydroxyl Radical Death Pathway. *Antimicrobial Agents and Chemotherapy*. 2012; 56(11):5642–5649. [PubMed: 22908157]
21. Azad MA, et al. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. *Biochem Pharmacol*. 84(3):278–291. [PubMed: 22587817]
22. Cao G, Ali FE, Chiu F, Zavascki AP, Nation RL, Li J. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. *J Antimicrob Chemother*. 2008; 62(5):1009–1014. [PubMed: 18765414]
23. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography. *Antimicrobial Agents and Chemotherapy*. 2003; 47(4):1364–1370. [PubMed: 12654671]


24. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*. 2006; 50(6): 1953–1958. [PubMed: 16723551]
25. Velkov T, et al. Surface changes and polymyxin interactions with a resistant strain of *Klebsiella pneumoniae*. *Innate Immunity*. 2013 in Press.
26. Li J, et al. Heteroresistance to Colistin in Multidrug-Resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2006; 50(9):2946–2950. [PubMed: 16940086]
27. EUCAST ECoAST. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. *Clinical Microbiology and Infection*. 2003; 9(8):ix–xv.
28. Dancy GF, Levine AE, Shapiro BM. The NADH dehydrogenase of the respiratory chain of *Escherichia coli*. I. Properties of the membrane-bound enzyme, its solubilization, and purification to near homogeneity. *Journal of Biological Chemistry*. 1976; 251(19):5911–5920. [PubMed: 786986]
29. Matsushita K, Ohnishi T, Kaback HR. NADH-ubiquinone oxidoreductases of the *Escherichia coli* aerobic respiratory chain. *Biochemistry*. 1987; 26(24):7732–7737. [PubMed: 3122832]
30. Copelan, RA. Evaluation of Enzyme Inhibition in Drug Discovery: A Guide for Medicinal Chemist and Pharmacologist - Second Edition. Second Edition. A John Wiley & Sons, Inc Publication; 2013. p. 57-201.
31. Dimroth P, Thomer A. A primary respiratory Na⁺ pump of an anaerobic bacterium: the Na⁺-dependent NADH:quinone oxidoreductase of *Klebsiella pneumoniae*. *Arch Microbiol*. 1989; 151(5):439–444. [PubMed: 2545175]
32. Melo AMP, Bandejas TM, Teixeira M. New Insights into Type II NAD(P)H:Quinone Oxidoreductases. *Microbiology and Molecular Biology Reviews*. 2004; 68(4):603–616. [PubMed: 15590775]
33. Krebs W, Steuber J, Gemperli AC, Dimroth P. Na⁺ translocation by the NADH:ubiquinone oxidoreductase (complex I) from *Klebsiella pneumoniae*. *Mol Microbiol*. 1999; 33(3):590–598. [PubMed: 10417649]
34. Steuber J, Schmid C, Rufibach M, Dimroth P. Na⁺ translocation by complex I (NADH:quinone oxidoreductase) of *Escherichia coli*. *Mol Microbiol*. 2000; 35(2):428–434. [PubMed: 10652103]
35. Shiemke AK, Arp DJ, Sayavedra-Soto LA. Inhibition of membrane-bound methane monooxygenase and ammonia monooxygenase by diphenyliodonium: implications for electron transfer. *J Bacteriol*. 2004; 186(4):928–937. [PubMed: 14761987]
36. Biagini GA, et al. Generation of quinolone antimalarials targeting the *Plasmodium falciparum* mitochondrial respiratory chain for the treatment and prophylaxis of malaria. *Proc Natl Acad Sci U S A*. 2012; 109(21):8298–8303. [PubMed: 22566611]
37. Bjorklof K, Zickermann V, Finel M. Purification of the 45 kDa, membrane bound NADH dehydrogenase of *Escherichia coli* (NDH-2) and analysis of its interaction with ubiquinone analogues. *FEBS Lett*. 2000; 467(1):105–110. [PubMed: 10664466]
38. Dong CK, et al. Type II NADH dehydrogenase of the respiratory chain of *Plasmodium falciparum* and its inhibitors. *Bioorg Med Chem Lett*. 2009; 19(3):972–975. [PubMed: 19097788]
39. Weinstein EA, et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *Proc Natl Acad Sci U S A*. 2005; 102(12):4548–4553. [PubMed: 15767566]
40. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. *Nature*. 2011; 469(7331):483–490. [PubMed: 21270886]
41. Fisher N, Bray PG, Ward SA, Biagini GA. Malaria-parasite mitochondrial dehydrogenases as drug targets: too early to write the obituary. *Trends Parasitol*. 2008; 24(1):9–10. [PubMed: 18024199]
42. Fisher N, Bray PG, Ward SA, Biagini GA. The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. *Trends Parasitol*. 2007; 23(7): 305–310. [PubMed: 17499024]
43. Biagini GA, et al. Generation of quinolone antimalarials targeting the *Plasmodium falciparum* mitochondrial respiratory chain for the treatment and prophylaxis of malaria. *Proceedings of the National Academy of Sciences*. 2012


44. Velazquez I, Pardo JP. Kinetic characterization of the rotenone-insensitive internal NADH: ubiquinone oxidoreductase of mitochondria from *Saccharomyces cerevisiae*. *Arch Biochem Biophys*. 2001; 389(1):7–14. [PubMed: 11370674]
45. Yano T, Li LS, Weinstein E, Teh JS, Rubin H. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). *J Biol Chem*. 2006; 281(17):11456–11463. [PubMed: 16469750]
46. Teh JS, Yano T, Rubin H. Type II NADH: menaquinone oxidoreductase of *Mycobacterium tuberculosis*. *Infect Disord Drug Targets*. 2007; 7(2):169–181. [PubMed: 17970227]
47. Eschemann A, Galkin A, Oettmeier W, Brandt U, Kerscher S. HDQ (1-Hydroxy-2-dodecyl-4(1H)quinolone), a High Affinity Inhibitor for Mitochondrial Alternative NADH Dehydrogenase: Evidence for A Ping-Pong Mechanism. *Journal of Biological Chemistry*. 2005; 280(5):3138–3142. [PubMed: 15533932]





Polymyxin B1=6-methyl-octanoic fatty acyl


Polymyxin B2=6-methyl-heptanoic fatty acyl

Polymyxin B R6=  **D-Phe**

Colistin R1=  **Dab**

Colistin E R6=  **D-Leu**

CMS= 



Ubiquinone Q1

Figure 1.

Chemical structures of the compounds used in this study. Polymyxin residues: Thr: threonine; Leu: leucine; Phe: phenylalanine; Dab: α , γ -diaminobutyric acid. CMS=colistin methanesulfonate.




Figure 2. Concentration-dependent inhibition of NDH-2 activity in Gram-negative bacterial inner membrane preparations by polymyxin B. *E. coli* DH5α (●), *K. pneumoniae* ATCC 13883 (■), *K. pneumoniae* ATCC 13883^R (▲) and *A. baumannii* ATCC 19606 (▼). Data are presented as the percentage of control activity in the absence of inhibitor. The experiments were performed in triplicate (shown as the mean ± S.D).




Figure 3. (A) Lineweaver-Burk plot showing mixed inhibition by polymyxin B of Q_1 dependent NDH-2 activity. (B) Lineweaver-Burk plot showing non-competitive inhibition by polymyxin B of NADH dependent NDH-2 activity.

Table 1

IC₅₀ values for the inhibition by polymyxins of NDH-2 oxidase activity in the inner membranes of Gram-negative bacteria.

Strains	IC ₅₀ (μM) *			
	<i>E. coli</i> DH5α	<i>K. pneumoniae</i> ATCC 13883	** <i>K. pneumoniae</i> ATCC 13883 ^R	<i>A. baumannii</i> ATCC19606
Polymyxin B	49.8±19.6	168±18.6	117±18.7	167±9.4
Polymyxin B1	44.6±16.9	ND	ND	ND
Polymyxin B2	56.9±25.7	ND	ND	ND
Colistin	251±66.1	376±50.0	359±81.8	346±62.6
Polymyxin B nona-peptide	NI	NI	NI	NI
Colistin nona-peptide	NI	NI	NI	NI
Colistin methanesulfonate	NI	NI	NI	NI

ND, Not determined.

NI, No inhibition.

* Mean ± S.D, n=3

** *K. pneumoniae* ATCC 13883^R is colistin-resistant variant of *K. pneumoniae* ATCC 13883 after serial exposure to colistin-containing media (see methodology).